Objective To study the efficacy and safety of continuous conversion of tenofovir fumarate(TDF)and TDF to propofol fumarate(TAF)in primary treatment of chronic hepatitis B(CHB).Methods 90 treatment-naive CHB patients attending the hospital from June 2018 to June 2023 were selected.According to the principle of sex,age,hepatitis B virus nucleic acid(HBV-DNA)load,and liver hardness(LSM),the baseline data were comparable in TDF group,30 in TAF group and 30 in conversion group.Clinical data were collected from the three groups and analyzed for clinical data at 24,48,72 and 96 weeks.Results At 24,48,72,DNA load,HBV-DNA turn rate,and LSM(P＞0.05)in three groups:ALT and AST(P＜0.05).Results of ALP and ALT relapse after 24 and 48 weeks(P＞0.05)and ALP and ALT relapse after 72 and 96 weeks(P＜0.05).After 24,48,72,96 weeks,the three groups showed no difference in BUN,Cr,UA,and β 2-MG(P＞0.05)after 24 weeks of treatment;not(P＞0.05);after 48,72,and 96 weeks of treatment(P＜0.05),the improvement in U β 2-MG was more evident with the increase of treatment time.Conclusion In the clinical diagnosis and treatment of CHB patients,TAF liver function recovery rate is better,renal tubular safety is higher,and conversion therapy can achieve n o less efficacy than continuous application of TDF and better renal safety.
NETL
NSTL
万方数据
